Journal: RSC Advances

Article Title: A MoS 2 based silver-doped ZnO nanocomposite and its antibacterial activity against β-lactamase expressing Escherichia coli †

doi: 10.1039/d2ra00163b

Figure Lengend Snippet: Minimum inhibitory concentrations (MICs) of ZO, AZO, and AZM against multidrug-resistant (MDR) E. coli

Article Snippet: ATCC BAA-2469 , ETP, IMP , bla NDM-1 , >250 , 125 , 15.63.

Techniques:

Journal: Frontiers in Microbiology

Article Title: Evaluation of the Immunochromatographic NG-Test Carba 5, RESIST-5 O.O.K.N.V., and IMP K -SeT for Rapid Detection of KPC-, NDM-, IMP-, VIM-type, and OXA-48-like Carbapenemase Among Enterobacterales

doi: 10.3389/fmicb.2020.609856

Figure Lengend Snippet: Reference strains used in this study.

Article Snippet: ATCC BAA 2469 , E. coli , NDM-1 , NDM , NDM.

Techniques:

Journal: eLife

Article Title: A drug repurposing approach reveals targetable epigenetic pathways in Plasmodium vivax hypnozoites

doi: 10.7554/eLife.98221

Figure Lengend Snippet: ( A ) Index chart depicting the primary screen of the ReFRAME library against P. vivax hypnozoites in an 8-day assay. Hypnozoite counts were normalized by mean quantity per well for each plate ( Z -score). Teal: library, black: DMSO, red: 1 μM monensin. ( B ) Dose–response curves for cadralazine against P. vivax and P. cynomolgi liver forms in 8-day assays at the IPC, UGA, and NITD. All replicate wells were plotted together from all independent experiments ( n = 3 for P. vivax at IPC, n = 1 for P. vivax at NITD, n = 2 for P. cynomolgi at UGA, and n = 4 for P. cynomolgi at NITD), bars represent SEM. Figure 1—source data 1. Source data for and supporting figures.

Article Snippet: Select hits were shared with the Novartis Institute for Tropical Diseases (NITD), where the hypnozonticidal activity and potency of cadralazine (pEC 50 = 6.09 ± 0.45), hydralazine (pEC 50 = 6.20), and poziotinib (pEC 50 = 6.17) were independently confirmed in a similar 8-day P . vivax screening platform using a P. vivax case from southern Thailand ( , ).

Techniques:

Journal: eLife

Article Title: A drug repurposing approach reveals targetable epigenetic pathways in Plasmodium vivax hypnozoites

doi: 10.7554/eLife.98221

Figure Lengend Snippet: ( A ) Index chart from with phosphatidylinositol 4-kinase inhibitor (PI4Ki) KDU691 or MMV390048, tafenoquine, and atovaquone controls added. Teal circle: library, black square: DMSO, pink triangle: 1 μM monensin, light green inverted triangle: 1 μM P4Ki, black diamond: 1 μM atovaquone, purple square: 10 μM tafenoquine. Some hits discussed in this report are noted with black circles; P: poziotinib, B: budralazine, H: hydralazine, C: cadralazine. ( B ) Simple linear regression correlating Z -factor with average hypnozoite count per well. ( C ) Structures of hits which confirmed to be active against P. vivax hypnozoites in dose–response assays; blue: hydralazine analogs, purple: other novel hits, green: re-discovery of compounds previously demonstrated to have hypnozonticidal activity in vitro or antirelapse activity in vivo.

Article Snippet: Select hits were shared with the Novartis Institute for Tropical Diseases (NITD), where the hypnozonticidal activity and potency of cadralazine (pEC 50 = 6.09 ± 0.45), hydralazine (pEC 50 = 6.20), and poziotinib (pEC 50 = 6.17) were independently confirmed in a similar 8-day P . vivax screening platform using a P. vivax case from southern Thailand ( , ).

Techniques: Activity Assay, In Vitro, In Vivo

Journal: eLife

Article Title: A drug repurposing approach reveals targetable epigenetic pathways in Plasmodium vivax hypnozoites

doi: 10.7554/eLife.98221

Figure Lengend Snippet: Mean plasma concentration of cadralazine was measured in three male rhesus macaques after oral dosing. Plasma was collected following a 1 mg/kg dose, and again following a 30 mg/kg dose. Bars represent SD. The approximate IC 50 and IC 90 from P. vivax hypnozoite assays are indicated.

Article Snippet: Select hits were shared with the Novartis Institute for Tropical Diseases (NITD), where the hypnozonticidal activity and potency of cadralazine (pEC 50 = 6.09 ± 0.45), hydralazine (pEC 50 = 6.20), and poziotinib (pEC 50 = 6.17) were independently confirmed in a similar 8-day P . vivax screening platform using a P. vivax case from southern Thailand ( , ).

Techniques: Clinical Proteomics, Concentration Assay

Journal: eLife

Article Title: A drug repurposing approach reveals targetable epigenetic pathways in Plasmodium vivax hypnozoites

doi: 10.7554/eLife.98221

Figure Lengend Snippet: ( A ) Isobologram of cadralazine and 5-azacytidine activity against hypnozoites in fixed ratios of 1:0, 8:1, 6:1, 4:1, 2:1, 1:1, 1:2, 1:4, 1:6, 1:8, and 0:1, bars represent SD of FICs from two independent experiments. ( B ) Dose–response curves for cadralazine at the most synergistic fixed ratios (2:1, 4:1, and 8:1) against hypnozoites. Cadralazine alone is represented as 1:0, 5-azacytidine alone is represented as 0:1 and plotted on the cadralazine chart for comparison. Left and right charts represent two independent experiments, bars represent replicate wells at each dose. Figure 2—source data 1. Source data for and supporting figures.

Article Snippet: Select hits were shared with the Novartis Institute for Tropical Diseases (NITD), where the hypnozonticidal activity and potency of cadralazine (pEC 50 = 6.09 ± 0.45), hydralazine (pEC 50 = 6.20), and poziotinib (pEC 50 = 6.17) were independently confirmed in a similar 8-day P . vivax screening platform using a P. vivax case from southern Thailand ( , ).

Techniques: Activity Assay, Comparison

Journal: eLife

Article Title: A drug repurposing approach reveals targetable epigenetic pathways in Plasmodium vivax hypnozoites

doi: 10.7554/eLife.98221

Figure Lengend Snippet: Dose–response curves for cadralazine with all fixed ratios of 5-azacytidine against P. vivax hypnozoites. Cadralazine alone is represented as 1:0, 5-azacytidine alone is represented as 0:1 and plotted on the cadralazine chart for comparison. Left and right charts represent two independent experiments.

Article Snippet: Select hits were shared with the Novartis Institute for Tropical Diseases (NITD), where the hypnozonticidal activity and potency of cadralazine (pEC 50 = 6.09 ± 0.45), hydralazine (pEC 50 = 6.20), and poziotinib (pEC 50 = 6.17) were independently confirmed in a similar 8-day P . vivax screening platform using a P. vivax case from southern Thailand ( , ).

Techniques: Comparison

Journal: eLife

Article Title: A drug repurposing approach reveals targetable epigenetic pathways in Plasmodium vivax hypnozoites

doi: 10.7554/eLife.98221

Figure Lengend Snippet: ( A ) Hypnozonticidal potency comparison of 12 ReFRAME hits in 8- and 12-day 1-ABT dose–response confirmation assays. Cadralazine, plasmocid, and pidralazine potencies were unaffected by assay version, while MS-0735 was less potent, and poziotinib was more potent, in the 12-day 1-ABT assay. Budralazine, dramedilol, RGH-5526, dihydralazine, todralazine, endralazine, and mopidralazine were inactive (pEC 50 <5) regardless of assay version. ( B ) Dose–response chart of poziotinib activity in the 12-day 1-ABT assay, pEC 50 against hypnozoites = 6.05. Bars represent SEM.

Article Snippet: Select hits were shared with the Novartis Institute for Tropical Diseases (NITD), where the hypnozonticidal activity and potency of cadralazine (pEC 50 = 6.09 ± 0.45), hydralazine (pEC 50 = 6.20), and poziotinib (pEC 50 = 6.17) were independently confirmed in a similar 8-day P . vivax screening platform using a P. vivax case from southern Thailand ( , ).

Techniques: Comparison, Activity Assay